KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Income from Continuing Operations: 2013-2025

Historic Income from Continuing Operations for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to -$90.9 million.

  • Xenon Pharmaceuticals' Income from Continuing Operations fell 44.76% to -$90.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$320.2 million, marking a year-over-year decrease of 50.05%. This contributed to the annual value of -$248.2 million for FY2024, which is 36.07% down from last year.
  • Xenon Pharmaceuticals' Income from Continuing Operations amounted to -$90.9 million in Q3 2025, which was down 7.31% from -$84.7 million recorded in Q2 2025.
  • Xenon Pharmaceuticals' 5-year Income from Continuing Operations high stood at -$15.4 million for Q3 2021, and its period low was -$90.9 million during Q3 2025.
  • Its 3-year average for Income from Continuing Operations is -$61.0 million, with a median of -$57.9 million in 2024.
  • Data for Xenon Pharmaceuticals' Income from Continuing Operations shows a maximum YoY tumbled of 12,533.71% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Xenon Pharmaceuticals' Income from Continuing Operations stood at -$25.6 million in 2021, then tumbled by 46.45% to -$37.4 million in 2022, then declined by 19.51% to -$44.7 million in 2023, then slumped by 77.77% to -$79.5 million in 2024, then plummeted by 44.76% to -$90.9 million in 2025.
  • Its Income from Continuing Operations was -$90.9 million in Q3 2025, compared to -$84.7 million in Q2 2025 and -$65.0 million in Q1 2025.